These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Phase 0 clinical trials in oncology: a paradigm shift for early drug development? Takimoto CH Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251 [TBL] [Abstract][Full Text] [Related]
5. The Challenge of Developing New Therapies for Childhood Cancers. Balis FM Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032 [TBL] [Abstract][Full Text] [Related]
6. Assessment of toxicity in cooperative oncology clinical trials: the long and short of it. Gwede CK; Johnson DJ; Daniels SS; Trotti A J Oncol Manag; 2002; 11(2):15-21. PubMed ID: 11989815 [TBL] [Abstract][Full Text] [Related]
7. Computer-aided documentation and therapy planning in pediatric oncology. Wiedemann T; Knaup P; Bachert A; Creutzig U; Haux R; Schilling F Stud Health Technol Inform; 1998; 52 Pt 2():1306-9. PubMed ID: 10384671 [TBL] [Abstract][Full Text] [Related]
8. [Pediatric pharmacology: is treatment of children preceded by an adequate investigation?]. Rubio González A; Suárez Ochoa J; Azanza Perea J; Honorato Pérez J An Esp Pediatr; 1989 May; 30(5):359-62. PubMed ID: 2667410 [TBL] [Abstract][Full Text] [Related]
9. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. Hirschfeld S; Ho PT; Smith M; Pazdur R J Clin Oncol; 2003 Mar; 21(6):1066-73. PubMed ID: 12637472 [TBL] [Abstract][Full Text] [Related]
10. Ethical issues in cooperative cancer therapy trials from a statistical viewpoint. II. Specific issues. Shuster JJ; Krischer JP; Boyett JM Am J Pediatr Hematol Oncol; 1985; 7(1):64-70. PubMed ID: 4037245 [TBL] [Abstract][Full Text] [Related]
11. The role of the 'innovative therapies for children with cancer' (ITCC) European consortium. Zwaan CM; Kearns P; Caron H; Verschuur A; Riccardi R; Boos J; Doz F; Geoerger B; Morland B; Vassal G; Cancer Treat Rev; 2010 Jun; 36(4):328-34. PubMed ID: 20231057 [TBL] [Abstract][Full Text] [Related]
12. Economics of new oncology drug development. DiMasi JA; Grabowski HG J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942 [TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
15. Anesthetic considerations for the pediatric oncology patient--part 1: a review of antitumor therapy. Latham GJ; Greenberg RS Paediatr Anaesth; 2010 Apr; 20(4):295-304. PubMed ID: 20470332 [TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of granisetron (BRL43694) in nausea and vomiting induced by anticancer drugs--pediatrics]. Sawada T; Matsumura T; Mugishima H; Kaneko M; Ohira M; Sugimoto T; Onuma N; Sakurai M; Takeda T Gan To Kagaku Ryoho; 1999 Aug; 26(9):1295-304. PubMed ID: 10478183 [TBL] [Abstract][Full Text] [Related]
17. Legal requirements for drug testing in children in Germany. Hasskarl H Pediatr Pharmacol (New York); 1983; 3(3-4):361-6. PubMed ID: 6677882 [TBL] [Abstract][Full Text] [Related]
19. [Clinical trials and studies of the German Society for Paediatric Oncology and Haematology (GPOH) and the European Directive for the Implementation of Good Clinical Practice in the Conduct of Clinical Trials]. Graf N; Göbel U Klin Padiatr; 2004; 216(3):129-31. PubMed ID: 15175956 [No Abstract] [Full Text] [Related]